B2H is active in 2 different projects. Discover more here.

Oncocare Interreg


Interreg is one of the key instruments of the European Union (EU) supporting cooperation across borders through project funding. Its aim is to jointly tackle common challenges and find shared solutions in fields such as health, environment, research, education, transport, sustainable energy and more. The current programme is called Interreg V and covers the period 2014-2020.

Interreg project – OncoCare

The care of cancer patients is a growing challenge for our society. Despite decisive innovations in prevention and treatment, new cases and new diseases are increasing with population aging. In addition, the rapid progress in research continuously creates new areas of specialization. The patient can therefore only benefit from the best possible care if the centers cooperate or share their knowledge and expertise.


In addition to Bridge2Health (B2H), OncoCare brings together 7 other partners: the oncology centers of Belgian, Dutch and German hospitals, Centre Hospitalier Universitaire de Liège (CHU de Liège – lead partner), Jessa Ziekenhuis Hasselt (Jessa), Maastricht University Medical Center (MUMC +) and RWTH Aachen (UKA-RWTH), as well as the Universities of Liège (ULiège), Maastricht (MU) and Aachen (UKA-ECCA).

Objective and purpose

The aim of the OncoCare project is to improve the quality of cancer care throughout the Euregio Meuse-Rhine. The cross-border cooperation is intended to facilitate the access to innovative therapeutic approaches and personalized medicine against cancer. These objectives will be achieved by the implementation of various measures, structured in 3 actions:

Interreg Euregio Meuse-Rhine programme

The OncoCare project is a part of the Interreg Euregio Meuse-Rhine Program (https://www.interregemr.eu/about-interreg), a European Union funding program that addresses disparities between regions and encourages cross-border collaboration. Its objective is the economic, social and territorial development of Europe’s regions.

Interreg is managed by the European Commission’s Directorate for Regional and Urban Policy (https://ec.europa.eu/regional_policy/en/funding/erdf/) and is funded by the European Regional Development Fund (ERDF) (https://ec.europa.eu/info/departments/regional-and-urban-policy_en).

For more information, visit the OncoCare project website (ajouter le lien www.oncocare.eu).



The objective of the BIOCYCLE project is to assess long-term treatment strategies in Crohn’s disease that will improve both safety and related costs while ensuring a constant level of efficacy during maintenance therapy.


The BIOCYCLE Project involves a consortium between 14 partners: CHU de Liège (coordinator of the project), (GETAID), UEDIN, SKANE, CHARITE, SHEBA, AFA, CCFA, IBDIM, UGOT, INSERM, UCL, B2H, OXFORD

Objective and purpose

Crohn’s disease is a chronic longstanding disease that can’t be cured with current available treatments. The aim of long-term treatment is to fully control the symptoms and avoid the progression of intestinal damage. Currently, the preferred strategy for moderate-severe disease is a combination therapy with anti-TNFα and anti-metabolites (immunosuppressant). This long-term treatment may lead to cost and safety issues. The BIOCYCLE action will assess the efficacy, safety, effectiveness and feasibility of either anti-TNFα or immunosuppressant withdrawal in those patients thanks to several actions:

H2020 program

Horizon 2020 is the financial instrument implementing the Innovation Union, a Europe 2020 flagship initiative aimed at securing Europe’s global competitiveness. By coupling research and innovation, H2020 is helping to achieve this with its emphasis on excellent science, industrial leadership and tackling societal challenges.

For more information, visit the BIOCYCLE project website (ajouter le lien www.biocycle.eu).



wallonia logo


[1]  This project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633168 – BIOCYCLE (PHC-13-2014).